MetaCap

Dermata Therapeutics (DRMA) vs Traws Pharma (TRAW)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Traws Pharma is the larger company by market cap ($2.7 million vs $2.5 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DRMA-54.51%TRAW-63.47%
+3%-32%-67%
Oct 7, 20261 yearNov 20, 2026
DRMA-50.05%TRAW-60.69%
+3%-30%-64%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DRMA versus TRAW key metrics
MetricDRMATRAW
Share price$0.5095$0.175
Market cap$2.51M$2.69M
1-day change-4.23%-23.91%
EPS (TTM)$-3.28$-1.71
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.79M
Revenue growth (YoY)—+1134.51%
Net income (latest FY)$-7.56M$9.17M
Operating margin—-640.68%
Net margin—328.67%
52-week high$4.66$3.23
52-week low$0.50$0.1698
Distance from 52-week high-89.07%-94.58%
Analyst consensusnonenone
Avg. price target upside+685.08%+471.43%
Average volume2.78M610.04K
Shares outstanding4.93M15.37M
Employees94
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Dermata Therapeutics

DRMA stock →

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

About Traws Pharma

TRAW stock →

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

DRMA vs TRAW FAQ

Which is bigger, Dermata Therapeutics or Traws Pharma?

Traws Pharma (TRAW) is larger, with a market capitalization of $2.69M compared with $2.51M for Dermata Therapeutics (DRMA).

Are Dermata Therapeutics and Traws Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons